Transfection

We collaborate with Lonza, who offers an improved electroporation technology, the NucleofectorTM Technology. The technology was originally introduced into the market by legacy Amaxa in 2001. By using the nucleofector technology enables researchers to transfection primary cells, stem cells, neurons, and cell lines, that have traditionally been difficult to transfect via electroporation and other non-viral transfection methods. In recent years, this has opened novel opportunities for research in  diseases and therapeutic development, including the advancement of gene therapies, immunotherapies, and stem cell generation.